This is an aggregated industry headline. Read the full story at BioPharma Dive →
FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices
Regulators say the telehealth company illegally shared patients' health data with advertisers and misled its customers. Hims & Hers hit back, calling the claims "baseless."
By BioPharma Dive
· Jul 30, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, co…
The WeekFierceBiotech ↗
Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, co…
The WeekBriefing
Three Asia-linked developments stood out: a CEO exit at Legend, a quickly deleted Merck trial posting, and an …